Clinical solution for accurate detection of hepatobiliary tumors
Primary liver cancer(Primary Liver Cancer, PLC)
Due to the insidious onset, less than 30% of liver cancer patients are suitable for radical treatment (surgical treatment) upon initial diagnosis. Systemic anti-tumor therapy plays an important role in the treatment of advanced liver cancer.
China
Incidence：367,700/No. 4mortality rate：316,500/No. 2
One of the most common malignant tumors in the world
Biliary tract tumors( biliary tract carcinoma, BTC)
Half of the patients with biliary tumors are already in the advanced stage when diagnosed, and surgery is currently the only effective means of radical cure. For metastatic or unresectable biliary tumors, patients can benefit from targeted therapy. As of December 2022, several targeted drugs have been approved for use in biliary tumors in my country.
3% of digestive system tumors
During consultation 10% of patients have access to surgery
50% The patient was already in the advanced stage when diagnosed, and the survival period<1 year
Postoperative recurrence rate67%
Detection targets and targeted drugs
Ordering Information
121020012 Hepatobiliary Malignant Tumor Gene Mutations Digital PCR Detection Kit
Equipment and Supplies
N10001.3 Naica® digital PCR system-3 color
N10001.6 Naica® digital PCR system-6 color
N30027.0 Nio™+Ultimate dPCR
C16011 Ruby Chips
C14012 Sapphire Chips
*For research use only
Workflow
Sample collection
PCR system configuration and sample addition
Droplet generation and expansion
